1. Most Discussed
  2. Gainers & Losers
RHS 27.5¢

News: Reproductive Health Science products to be sold in Israel, southern Africa

  1. Reproductive Health Science (ASX:RHS) has now entered into key new markets by signing a 3-year exclusive distribution agreements with distributors based in Israel and South Africa, for the sale of its lead product EmbryoCellect™.

    EmbryoCellect™ is a pre-implantation genetic screening (PGS) kit designed to increase the chance of a successful In-Vitro Fertilisation (IVF) cycle.

    Launched in 2014, EmbryoCellectTM contains reagents for 20 tests at a list price of AUD$3,600 per kit.

    The international IVF rate varies from country to country but has been estimated to continue to grow at 10% per annum through to 2020.

    Israel is a key market with around 32,000 cycles of IVF are undertaken each year, as the Israeli Government provides free, unlimited IVF procedures for women up to the age of 45 for up to two babies.

    This policy has made Israel the biggest user of IVF per capita in the world, where 4% of children are IVF babies, compared to 1% in the U.S.

    RHS will team with Al-Rad Medical for the sale of EmbryoCellect™ in Israel and the Palestinian Authority.

    In Southern Africa, the company signed an agreement with Delfran Pharmaceuticals in the South African Development Community (SADC) countries.

    These include Angola, Botswana, Democratic Republic of Congo, Lesotho, Madagascar, Malawi, Mauritius, Mozambique, Namibia, Seychelles, South Africa, Swaziland, United Republic of Tanzania, Zambia and Zimbabwe.

    The South African Register of Assisted Reproductive Techniques Committee reports that in 2011 there were more than 5,600 IVF cycles conducted by the 14 participating South African IVF clinics, representing an almost 15% increase from 2010.

     

DISCLAIMER:
Before making any financial decisions based on what you read, always consult an advisor or expert.

The HotCopper website is operated by Report Card Pty Ltd. Any information posted on the website has been prepared without taking into account your objectives, financial situation or needs and as such, you should before acting on the information or advice, consider the appropriateness of the information or advice in relation to your objectives, financial situation or needs. Please be aware that any information posted on this site should not be considered to be financial product advice.

From time to time comments aimed at manipulating other investors may appear on these forums. Posters may post overly optimistic or pessimistic comments on particular stocks, in an attempt to influence other investors. It is not possible for management to moderate all posts so some misleading and inaccurate posts may still appear on these forums. If you do have serious concerns with a post or posts you should report a Terms of Use Violation (TOU) on the link above. Unless specifically stated persons posting on this site are NOT investment advisors and do NOT hold the necessary licence, or have any formal training, to give investment advice.

Top

Thank you for visiting HotCopper

We have detected that you are running ad blocking software.


HotCopper relies on revenue generated from advertisers. Kindly disable your ad blocking software to return to the HotCopper website.

I understand, I have disabled my ad blocker. Let me in!

Need help? Click here for support.